IB-367 pre-treatment improves the in vivo efficacy of teicoplanin and daptomycin in an animal model of wounds infected with meticillin-resistant Staphylococcus aureus

Journal of Medical Microbiology

Volumn 62, Issue PART10, 2013, Pages 1552-1558

  Cirioni, Oscar ^a   Silvestri, Carmela ^a   Pierpaoli, Elisa ^b   Barucca, Alessandra ^b   Kamysz, Wojciech ^c   Ghiselli, Roberto ^a   Scalise, Alessandro ^a   Brescini, Lucia ^a   Castelli, Pamela ^a   Orlando, Fiorenza ^b   Kamysz, Elzbieta ^d   Guerrieri, Mario ^a   Giacometti, Andrea ^a   Provinciali, Mauro ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF GDA SK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; DAPTOMYCIN; ISEGANAN; TEICOPLANIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; CELL COUNT; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; IN VIVO STUDY; LEUKOCYTE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; WOUND INFECTION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL LOAD; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN; TREATMENT OUTCOME; WOUND INFECTION;

EID: 84884496607     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.057414-0     Document Type: Article

References (35)

1. Allaker, R. P. (2008). Host defence peptides-a bridge between the innate and adaptive immune responses. Trans R Soc Trop Med Hyg 102, 3-4.
2. Auvynet, C. & Rosenstein, Y. (2009). Multifunctional host defense peptides: antimicrobial peptides, the small yet big players in innate and adaptive immunity. FEBS J 276, 6497-6508.
3. Babizhayev, M. A. (2010). New concept in nutrition for the maintenance of the aging eye redox regulation and therapeutic treatment of cataract disease; synergism of natural antioxidant imidazole-containing amino acid-based compounds, chaperone, and glutathione boosting agents: a systemic perspective on aging and longevity emerged from studies in humans. Am J Ther 17, 373-389.
4. Boman, H. G. (2003). Antibacterial peptides: basic facts and emerging concepts. J Intern Med 254, 197-215.
5. Bowdish, D. M., Davidson, D. J., Scott, M. G. & Hancock, R. E. W. (2005). Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 49, 1727-1732.
6. Breen, J. O. (2010). Skin and soft tissue infections in immunocompetent patients. Am Fam Physician 81, 893-899.
7. Carretero, M., Escámez, M. J., García, M., Duarte, B., Holguín, A., Retamosa, L., Jorcano, J. L., Río, M. D. & Larcher, F. (2008). In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J Invest Dermatol 128, 223-236.
8. Cenci, E., Pericolini, E., Mencacci, A., Conti, S., Magliani, W., Bistoni, F., Polonelli, L. & Vecchiarelli, A. (2006). Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J Leukoc Biol 79, 40-45.
9. Chen, Q., Wade, D., Kurosaka, K., Wang, Z. Y., Oppenheim, J. J. & Yang, D. (2004). Temporin A and related frog antimicrobial peptides use formyl peptide receptor-like 1 as a receptor to chemoattract phagocytes. J Immunol 173, 2652-2659.
10. Cho, Y., Turner, J. S., Dinh, N. N. & Lehrer, R. I. (1998). Activity of protegrins against yeast-phase Candida albicans. Infect Immun 66, 2486-2493.
11. CLSI (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved standard M7-A6. Wayne, PA: Clinical and Laboratory Standards Institute.
12. De la Fuente, M. & Victor, V. M. (2000). Anti-oxidants as modulators of immune function. Immunol Cell Biol 78, 49-54.
13. De Smet, K. & Contreras, R. (2005). Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 27, 1337-1347.
14. Eliopoulos, G. M. (2009). Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. J Infect 59 (Suppl. 1), S17-S24.
15. Enoch, S. & Harding, K. G. (2003). Science behind the removal of barriers to healing. Wounds 15, 213-229.
16. Fields, G. B. & Noble, R. L. (1990). Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res 35, 161-214.
17. Giacometti, A., Cirioni, O., Ghiselli, R., Mocchegiani, F., D'Amato, G., Del Prete, M. S., Orlando, F., Kamysz, W., Lukasiak, J. & other authors (2003). Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats. Gut 52, 874-878.
18. Hancock, R. E. W. (2001). Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1, 156-164.
19. Hancock, R. E. W. & Scott, M. G. (2000). The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci U S A 97, 8856-8861.
20. Ippolito, G., Leone, S., Lauria, F. N., Nicastri, E. & Wenzel, R. P. (2010). Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis 14 (Suppl 4), S7-S11.
21. Kaminogawa, S. & Nanno, M. (2004). Modulation of immune functions by foods. Evid Based Complement Alternat Med 1, 241-250.
22. Koczulla, R., von Degenfeld, G., Kupatt, C., Krötz, F., Zahler, S., Gloe, T., Issbrücker, K., Unterberger, P., Zaiou, M. & other authors (2003). An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111, 1665-1672.
23. Lowy, F. D. (2003). Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111, 1265-1273.
24. Messina, C., Kirkpatrick, D., Fitzgerald, P. A., O'Reilly, R. J., Siegal, F. P., Cunningham-Rundles, C., Blaese, M., Oleske, J., Pahwa, S. & Lopez, C. (1986). Natural killer cell function and interferon generation in patients with primary immunodeficiencies. Clin Immunol Immunopathol 39, 394-404.
25. Mookherjee, N. & Hancock, R. E. (2007). Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 64, 922-933.
26. Pace, J. L. & Yang, G. (2006). Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol 71, 968-980.
27. Pertinhez, T. A., Conti, S., Ferrari, E., Magliani, W., Spisni, A. & Polonelli, L. (2009). Reversible self-assembly: a key feature for a new class of autodelivering therapeutic peptides. Mol Pharm 6, 1036-1039.
28. Pirofski, L. A. & Casadevall, A. (2006). Immunomodulators as an antimicrobial tool. Curr Opin Microbiol 9, 489-495.
29. Provinciali, M., Di Stefano, G. & Fabris, N. (1992). Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional 51CR release assay. J Immunol Methods 155, 19-24.
30. Provinciali, M., Cirioni, O., Orlando, F., Pierpaoli, E., Barucca, A., Silvestri, C., Ghiselli, R., Scalise, A., Brescini, L. & other authors (2011). Vitamin E improves the in vivo efficacy of tigecycline and daptomycin in an animal model of wounds infected with meticillin-resistant Staphylococcus aureus. J Med Microbiol 60, 1806-1812.
31. Raad, I., Alrahwan, A. & Rolston, K. (1998). Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis 26, 1182-1187.
32. Salzet, M. (2002). Antimicrobial peptides are signaling molecules. Trends Immunol 23, 283-284.
33. Simonetti, O., Cirioni, O., Goteri, G., Ghiselli, R., Silvestri, C., Orlando, F., Scalise, A., Saba, V., Scalise, G. & other authors (2008). Temporin A is effective in the MRSA infected wounds in mice through bactericidial activity and acceleration of wound repair in a murine model. Peptides 29, 520-528.
34. Steenbergen, J. N., Alder, J., Thorne, G. M. & Tally, F. P. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55, 283-288.
35. Stevens, D. L. (2009). Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. J Infect 59 (Suppl 1), S32-S39.